This Event is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Key Event Title
Synthesis, De Novo FA
|Level of Biological Organization
Key Event Components
|fatty acid biosynthetic process
Key Event Overview
AOPs Including This Key Event
|Role of event in AOP
|Point of Contact
|LXR Activation to Liver Steatosis
|Marina Goumenou (send email)
|Not under active development
|LXR activation leads to liver steatosis
|John Frisch (send email)
|Under development: Not open for comment. Do not cite
Key Event Description
A number of pathways and a great number of enzymes like GK, L-PK, ACC, FAS and SCD-1 are involved in the de novo FA synthesis . As it is already discussed above these enzymes are induced by LXR agonists (FAS, SCD1), the SREBP-1c (GK, ACC, FAS) and the ChREBP (L-PK, ACC, FAS) leading to enhancement of the de novo FA synthesis.
Figure 1. Metabolic pathway for de novo FA synthesis and TG formation 
As proposed from Diraison et al 1997 the de novo FA synthesis contributes maximum 5% to the synthesis of FA and TG under normal conditions. Conditions associated with high rates of lipogenesis, such as low fat - high carbohydrate (LF/HC) diet, hyperglycemia, and hyperinsulinemia are associated with a shift in cellular metabolism from lipid oxidation to TG esterification, thereby increasing the availability of TGs derived from VLDL synthesis and secretion.
How It Is Measured or Detected
Domain of Applicability
- Postic & Girard 2008